Ixazomib

Investigating the efficacy of twice weekly ixazomib plus pom-dex in R/R multiple myeloma 0:59
Investigating the efficacy of twice weekly ixazomib plus pom-dex in R/R multiple myeloma
Paul Richardson • 11 Dec 2022
The importance of real-world data in multiple myeloma 2:25
The importance of real-world data in multiple myeloma
Claudio Cerchione • 28 Sep 2022
Updates from a Phase II study evaluating zanubrutinib, ixazomib and dexamethasone in WM 4:00
Updates from a Phase II study evaluating zanubrutinib, ixazomib and dexamethasone in WM
Shuhua Yi • 26 Oct 2022
The current state of the art in R/R multiple myeloma: a European perspective 7:10
The current state of the art in R/R multiple myeloma: a European perspective
Claudio Cerchione • 24 Oct 2022
INSURE: pooled analysis of patients with R/R multiple myeloma treated with IRd in the real-world 1:38
INSURE: pooled analysis of patients with R/R multiple myeloma treated with IRd in the real-world
Karthik Ramasamy • 30 Aug 2022
Key findings of the pooled analysis of the TOURMALINE-MM3 and MM4 trials 2:07
Key findings of the pooled analysis of the TOURMALINE-MM3 and MM4 trials
Bruno Paiva • 25 Aug 2022
An update on Alliance A061202: addition of ixazomib to pomalidomide-dexamethasone in R/R myeloma 1:09
An update on Alliance A061202: addition of ixazomib to pomalidomide-dexamethasone in R/R myeloma
Paul Richardson • 26 Aug 2022
IFM 2018-02: ixazomib + daratumumab in elderly frail patients with R/R multiple myeloma 4:23
IFM 2018-02: ixazomib + daratumumab in elderly frail patients with R/R multiple myeloma
Xavier Leleu • 10 Jun 2022
Results from the IFM 2014-01 trial: pomalidomide, dexamethasone & ixazomib in high-risk R/R myeloma 3:54
Results from the IFM 2014-01 trial: pomalidomide, dexamethasone & ixazomib in high-risk R/R myeloma
Xavier Leleu • 10 Jun 2022
Alliance A061202: POM-DEX vs IXA-POM-DEX in R/R multiple myeloma 2:06
Alliance A061202: POM-DEX vs IXA-POM-DEX in R/R multiple myeloma
Paul Richardson • 11 Jun 2022
Long-term follow-up of the TOURMALINE-MM1 trial 1:40
Long-term follow-up of the TOURMALINE-MM1 trial
Paul Richardson • 14 May 2022
The efficacy of ixazomib for the treatment of R/R myeloma 0:58
The efficacy of ixazomib for the treatment of R/R myeloma
Graham Jackson • 13 May 2022
Novel agents and clinical trials emerging for the treatment of AL amyloidosis 3:23
Novel agents and clinical trials emerging for the treatment of AL amyloidosis
Giampaolo Merlini • 10 May 2022
Treatment options for transplant-ineligble myeloma patients: the promise of combination therapies 1:42
Treatment options for transplant-ineligble myeloma patients: the promise of combination therapies
Graham Jackson • 3 Apr 2022
Managing multiple myeloma patients with del(17p) 1:46
Managing multiple myeloma patients with del(17p)
Rakesh Popat • 3 Apr 2022
Daratumumab in the treatment of high-risk MGUS and low-risk smoldering myeloma 1:38
Daratumumab in the treatment of high-risk MGUS and low-risk smoldering myeloma
Irene Ghobrial • 11 Dec 2021
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals